Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0001445

Celecoxib

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, CJ-016377, CP-598107, PF-00345549, PHA-00846533, SC-58635, YM-177

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H14F3N3O2S
CAS Number:
169590-42-5
Molecular Weight:
381.37
MDL number:
MFCD00941298
UNSPSC Code:
41116107
PubChem Substance ID:
329831427
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

celecoxib

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F

InChI

1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)

InChI key

RZEKVGVHFLEQIL-UHFFFAOYSA-N

Gene Information

human ... PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Celecoxib EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Celecoxib is a non-steroidal, anti-inflammatory drug (NSAID) and a cyclooxygenase-2 (COX-2) selective inhibitor. Celecoxib is at least 10-20 times more selective for COX-2 over COX-1.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001446

Celecoxib impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001447

Celecoxib impurity B, European Pharmacopoeia (EP) Reference Standard

PHR1683

Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material

1098515

Celecoxib Related Compound A, United States Pharmacopeia (USP) Reference Standard

1098526

Celecoxib Related Compound B, United States Pharmacopeia (USP) Reference Standard

1098504

Celecoxib, United States Pharmacopeia (USP) Reference Standard

1098537

Celecoxib Related Compound C, United States Pharmacopeia (USP) Reference Standard

1098570

Celecoxib Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP1230

Celecoxib, British Pharmacopoeia (BP) Reference Standard

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 1 - Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Leyte L Winfield et al.
Future medicinal chemistry, 4(3), 361-383 (2012-03-08)
Celecoxib is a multifaceted drug with promising anticancer properties. A number of studies have been conducted that implicate the compound in modulating the expression of Bcl-2 family members and mitochondria-mediated apoptosis. The growing data surrounding the role of celecoxib in
Manon C Zweers et al.
Arthritis research & therapy, 13(5), 239-239 (2011-10-01)
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, and synovial inflammation, causing substantial physical disability, impaired quality of life, and significant health care utilization. Traditionally, non-steroidal anti-inflammatory drugs (NSAIDs)
Paul L McCormack
Drugs, 71(18), 2457-2489 (2011-12-07)
Celecoxib (Celebrex®) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory/analgesic activity similar to that of nonselective NSAIDs, but without their upper gastrointestinal (GI) toxicity, which is thought to
Verena Jendrossek
Cancer letters, 332(2), 313-324 (2011-02-25)
Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor types, such as colorectal, breast, non-small cell lung, and prostate cancers. Up to now, the drug
Sheena Derry et al.
The Cochrane database of systematic reviews, 10(10), CD004233-CD004233 (2013-10-24)
This is an update of a review first published in The Cochrane Library in Issue 4, 2008, and updated in Issue 3, 2012. Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor usually prescribed for the relief of chronic pain in osteoarthritis
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service